---
title: "Tinlarebant (LBS-008) in Stargardt disease type 1: References"
description: "Reference list for the formulary evidence report on Tinlarebant (LBS-008) in Stargardt disease type 1. 65 cited documents."
canonical: "https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tinlarebant (LBS-008) in Stargardt disease type 1: References

<a id="references"></a>

## 5 References

1. [Abu Serhan et al. (2026)](https://link.springer.com/article/10.1186/s40942-026-00820-7)
2. [American Academy of Ophthalmology (2022)](https://www.aao.org/education/clinical-statement/guidelines-on-clinical-assessment-of-patients-with)
3. [ANZCTR ACTRN12624000031561](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000031561)
4. [ARVO Annual Meeting (2023)](https://investors.belitebio.com/static-files/a5527853-be5e-49c4-a007-c84e2850e85a)
5. [Aziz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11207193/)
6. [Belite Bio](https://belitebio.com/product-008/)
7. [Belite Bio (2023)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-results-24-month-phase-2-study-tinlarebant)
8. [Belite Bio (2024)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-additional-analysis-phase-2-study/)
9. [Belite Bio ASRS oral presentation announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-oral-presentation-asrs-annual-meeting)
10. [Belite Bio Commercial Day (2026)](https://investors.belitebio.com/static-files/5821cd0b-330c-4a61-877c-04009ccc254d)
11. [Belite Bio company presentation (2026)](https://investors.belitebio.com/static-files/837a64fe-a778-4209-9239-313d77a3aa0f)
12. [Belite Bio DRAGON topline results announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite/)
13. [Belite Bio FDA Breakthrough Therapy designation announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-fda-granting-breakthrough-therapy)
14. [Belite Bio FDA NDA acceptance announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-us-food-and-drug-administration-acceptance)
15. [Belite Bio first quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-first-quarter-2026-financial/)
16. [Belite Bio Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm)
17. [Belite Bio Japan NDA submission announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-submission-new-drug-application-ministry)
18. [Belite Bio NDA rolling submission completion announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-completes-rolling-submission-new-drug-application-us/)
19. [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial)
20. [Bernstein et al. (2026)](https://investors.belitebio.com/static-files/55440621-72d4-44c5-9719-7f53a28e8591)
21. [Bodenbender et al. (2025)](https://link.springer.com/article/10.1007/s00417-025-06884-9)
22. [Britten-Jones et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449819/)
23. [Cioffi (2025)](https://acs.digitellinc.com/live/35/session/563555)
24. [ClinicalTrials.gov NCT05244304](https://clinicaltrials.gov/study/NCT05244304)
25. [ClinicalTrials.gov NCT05266014](https://clinicaltrials.gov/study/NCT05266014)
26. [ClinicalTrials.gov NCT06388083](https://clinicaltrials.gov/study/NCT06388083)
27. [Dayma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12295471/)
28. [Edwards et al. (2026)](https://onlinelibrary.wiley.com/doi/10.1111/ceo.70050)
29. [FDA Orphan Drug Designations and Approvals (2017)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=601217)
30. [Federspiel et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29939824/)
31. [Fujinami et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37940365/)
32. [Gomes et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35975566/)
33. [Gong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257071/)
34. [Grigg et al. (2022)](https://iovs.arvojournals.org/article.aspx?articleid=2781626)
35. [Grigg et al. (2023)](https://iovs.arvojournals.org/article.aspx?articleid=2787663)
36. [Grigg et al. (2024)](https://iovs.arvojournals.org/article.aspx?articleid=2797066)
37. [Hoang et al. (2026)](https://iovs.arvojournals.org/article.aspx?articleid=2811812)
38. [Ibukun et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41773771/)
39. [Kay et al. (2026)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2853582)
40. [Knott et al. (2023)](https://www.valueinhealthjournal.com/article/S1098-3015%2823%2904098-6/fulltext)
41. [Kong et al. (2018)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2684573)
42. [Kootstra et al. (2026)](https://www.ovid.com/journals/acoph/fulltext/10.1111/aos.70072~mesopic-microperimetry-in-stargardt-disease-application-and)
43. [Mata et al. (2025)](https://karger.com/ore/article/68/1/555/938764/Bisretinoids-as-a-Source-of-Early-Photoreceptor)
44. [Mayo Clinic](https://www.mayo.edu/research/clinical-trials/cls-20571936)
45. [MedlinePlus Genetics](https://medlineplus.gov/genetics/condition/stargardt-macular-degeneration/)
46. [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)
47. [Ng et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03099-9)
48. [Palmgren et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/17469899.2026.2645188)
49. [Parameswarappa et al. (2026)](https://link.springer.com/article/10.1007/s40123-026-01407-z)
50. [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)
51. [Retina South Africa (2025)](https://retinasa.org.za/hope-on-the-horizon-for-stargardt-disease/)
52. [Roborel de Climens et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33305649/)
53. [Runhart et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9291619/)
54. [Selleck Chemicals](https://www.selleckchem.com/msds/MSDS_E6681_eu.pdf)
55. [Stanford Health Care](https://stanfordhealthcare.org/trials/p/NCT05244304.html)
56. [Stargardt disease patient-listening-session report (2022)](https://www.fda.gov/media/165186/download)
57. [Strauss et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26786511/)
58. [Strauss et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36764427/)
59. [Sui et al. (2025)](https://iovs.arvojournals.org/article.aspx?articleid=2805908)
60. [Terheyden et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36130585/)
61. [UCSF Health](https://www.ucsfhealth.org/care/conditions/stargardt-disease)
62. [UK Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/lbs-008-ct07/)
63. [UK Health Research Authority (2021)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-study-of-tinlarebant-as-treatment-for-adolescent-stargardt-disease/)
64. [Vaccaro et al. (2023)](https://access.portico.org/Portico/show?auId=pjbdch1zk14&viewFile=pdf)
65. [Waugh et al. (2018)](https://www.ncbi.nlm.nih.gov/books/NBK500486/?report=reader)

## Related pages
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Terms and abbreviations](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/terms-and-abbreviations.md)
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/executive-summary.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Product information and disease description](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/product-information-and-disease-description.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Clinical evidence](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/clinical-evidence.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Economic information and modeling report](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economics) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economics.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: prevalence by geography](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/prevalence) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/prevalence.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/cost-effectiveness-analyses.md)
